Perhaps an enzyme could be engineered that could do that. Or perhaps some sort of carrier protein could be engineered that would open up the bilirubin and change its polarity.
DR. DENNERY: Dr. Stevenson, part of the question that you must ask yourself is whether hemoglobin binding to carbon monoxide can interfere with your end-tidal carbon monoxide (ETCO) measurements. Hemoglobin is a known scavenger of carbon monoxide, and perhaps your measurements would be even higher if it weren't for the fact that when you hemolyze, you obviously have free hemoglobin that could possibly scavenge the carbon monoxide. This mechanism is used when we try to eliminate carbon monoxide by in vitro systems.
DR. STEVENSON:
That is a reasonable hypothesis. The body doesn't like to have free heme or hemoglobin floating around for very long. In fact, these relationships have been carefully studied, and the relationship between excretion rates of end-tidal concentrations of carbon monoxide and concentrations of carboxy hemoglobin under proximate state conditions suggest that mathematically they should be in understandable and highly predictable relationships; in fact, that's what we found. We have shown this in earlier studies in humans and also in animals.
DR. BHUTANI: The vigorous lactational support in the first 3 days has been effective in reducing the severity and jaundice in our infants. Could you comment on your experience with infants 48 to 72 hours old who have been delivered in the United States, in light of the effort there to reduce cesarean section by instrumented deliveries such as vacuum. With cesarean delivery, when there is bruising, the infants have headaches and they don't eat well. This combination leads to metastatic load.
DR. GARTNER: Infants who are vacuum extracted don't do well, and they do have a degree of bleeding under the scalp. When I see these infants, I anticipate problems. I wish obstetricians would discontinue this practice. Infants with cerebral hematomas and other significant bleeding have a significant increase in their bilirubin levels essentially equivalent to hemolysis, and they tend not to feel well.
Maternal drug use is another factor that often leads to poor breast-feeding. These are challenging situations that require a great deal of effort on the part of both the mother and the infant. Obviously getting as normal a delivery situation as possible is the ideal answer, but we are still going to have infants who are depressed and who don't feed well, and we need to find ways to help them. Sometimes these infants benefit from supplementation, although we try to minimize the need for that.
Original Article
Many people try to avoid exposure to cow's milk or soy milk because of potential allergy, which probably occurs in about 8% of the population, at least in the United States. Often a good lactation consultant can help compensate for the depression of infants and improve feeding.
All breast-fed infants -in fact, probably all infantsshould be seen at approximately 3 to 5 days of age. In the United States, most infants go home 48 hours after birth, so they should be seen 2 to 3 days after discharge. At that time the American Academy of Pediatrics recommends a formal evaluation of breast-feeding, which means observing the breast-feeding itself, observing for jaundice, and weighing the infant. Once they leave the hospital, many of these infants are not breast-feeding well and require careful monitoring.
DR. JOHNSON: There should also be follow-up evaluations at 1 week and 10 days after birth. All but two of the infants in the kernicterus registry that Dr. Brown and I have initiated were breast-fed. In those two, there was glucose-6-phosphate dehydrogenase (G6PD) deficiency.
DR. GARTNER: Breast-feeding has increased in the United States, but the support for and effectiveness of breast-feeding is still less than optimal.
DR. FANAROFF: Dr. Gartner, although you stated that you don't allow more than a 7% weight loss, in the United States, despite our best efforts, patients go home at 48 hours, and many infants have weight loss as high as 8% to 10% at that time.
DR. GARTNER: Much of the problem relates to a lack of education and support in the hospital. Frequency of breast-feeding is really not achieved at an optimal level in most American hospitals. A frequency of 10 to 12 times a day can be achieved with a good supportive full rooming in, but in reality the frequency is closer to eight times a day, which results in greater weight loss and more jaundice.
DR. MAISELS: Even with lactation help, achieving these levels of 10 to 12 times a day to minimize weight loss is difficult, even with the most motivated and committed women. A more practical approach may be to stress surveillance so that if a problem does arise, it can be corrected quickly with prompt intervention.
DR. WATCHKO: Dr. Kaplan, published data on infants with marked hyperbilirubinemia levels in the 30s and 40s indicate that the direct fraction seemed to be extremely low relative to the totals number. Since it's relatively straightforward to genotype patients now with regard to their promoter sequence with respect to the uridine disphosphoglucuronyltransferase (UDPGT), do we have any data on those affected infants?
DR. KAPLAN: I don't have any. Perhaps Dr. Chowdhury could comment.
DR. CHOWDHURY: If you set an arbitrary level of hyperbilirubinemia at 15, the data you saw, it requires not just the Gilbert-type promoter, but it needs some other thing to push it. However, if we look at only bilirubin absolute values, we find a substantial difference of average bilirubin levels between normal heterozygote and homozygote Gilbert syndrome when you leave out all cases of G6PD. This difference occurs in everyone.
Also, it doesn't take too much hemolysis to cause jaundice in Gilbert syndrome. In adults, 9 of 10 patients who are diagnosed with Gilbert's syndrome are male, although it is not an autosomal disorder. The slight difference of bilirubin production between males and females is reflected in those who have Gilbert syndrome versus those who just have the genotype. So it is not surprising that G6PD or anything else that would slightly increase the bilirubin load would cause jaundice.
DR. McDONAGH: Dr. Kaplan, you stated that bilirubin induces its own conjugation. How strong is the evidence for this? I believe some of it is based on older, less reliable studies. Along that same line, you imply that the amount of conjugates you see in the plasma reflects what's happening in the liver. However, you mustn't overlook renal excretion of the conjugates, which can vary. So the level of the conjugates in the plasma doesn't necessarily reflect the status of the liver.
DR. KAPLAN: Perhaps, but it's the best that we can do because the alternative is to do invasive studies of the liver.
DR. McDONAGH: What about assessing urine excretion? DR. KAPLAN: We haven't done that, but that's a reasonable possibility.
DR. STEVENSON: I would like to emphasize what's just been said about the slightly increased bilirubin production. I think it emphasizes that, when there is any limitation in conjugation, either naturally or for some genetic reason, what ordinarily would not be of great interest to the organism can actually be fairly catastrophic over time. Immediate transgression of these typical patterns, will develop over time, if someone is not paying attention, like there is not adequate follow-up beyond 48, 72 hours, some of these children will leave those trajectories later mainly because of these slight imbalances. So although it's not perfect with respect to the way things have been analyzed, I think that Dr. Kaplan has identified an important concept and given us some additional insight as to how this might work dynamically, even though I think the way to monitor that measure could be improved slightly.
DR. MAISELS: Dr. Gartner, what is your recommendation for a breast-feeding infant with a bilirubin level of 20 who seems to be doing well. The Academy guidelines say that phototherapy is indicated in infants with that high a level. Although the guideline is a suggestion, not a mandate, it allows for a wide range of safety. We also need to differentiate between infants with that level for a day and an infant with that level for 5 days. Data about length of exposure to those levels is limited, although Dr. Johnson 1 has some data suggesting that slightly preterm infants with bilirubin levels of above 15 for more than 48 hours were more likely to have developmental problems than those with that level for less than 48 hours. There are so many individual variations, however, that one [Pediatrics] that infants born at 36 to 37 weeks' gestation were at much greater risk for kernicterus with slightly elevated bilirubin levels of 20, 22, etc. As a partial answer to your question, I would be more aggressive in trying to lower the bilirubin level of a slightly premature infant with a level of 22, 23, who is breast-fed and otherwise healthy; a full-term infant with that same level might be more appropriately observed as long as there were no evidence of problems.
DR. STEVENSON: In that regard, the binding in that nearterm infant is different from that in the full-term infant. The level of circulation does not necessarily reflect the total amount of bilirubin that might be in the body; it may be that a large load is distributing into other tissues over time, so that what we are measuring does not reflect the total body load. It's important to pay careful attention to how much bilirubin there is in the total system, which may affect an infant's risk of having some other event take place that leads to an injuring set of circumstances.
DR. CASHORE: Could someone comment on some of Marilow's finding, especially in his first report in which he said that patients with a different form of Gilbert mutation, that is a form within the structure of the enzyme in several Japanese kindred, appeared to show a heterozygote disadvantage. The homozygous patients were the most severely affected, but the heterozygous patients seemed to have a greater deficiency of conjugating capacity than could be predicted by having only one normal gene. It was almost as if the abnormal gene were further interfering with bilirubin conjugation. He did not emphasize this possibility in his more recent publication [Pediatrics] . Could the heterozygote disadvantage vary among populations having different mutations, and could it also be greater than recognized? If, for example, the infant makes only predominantly monoconjugates, is it possible that the breast-fed infant might then reabsorb more of the bilirubin in that situation? DR. KAPLAN: I didn't mention the Oriental type of Gilbert syndrome, which is a different mutation. It's a mutation in the coding area. It causes the clinical form of Gilbert syndrome, similar to what we see in the West with the promoter variation. Whereas the Western form of Gilbert syndrome causes neonate hyperbilirubinemia when in combination with other factors, the Japanese type doesn't need this combination and causes hyperbilirubinemia in and of itself.
DR. CHOWDHURY: In Japan and most likely also in China and in Korea, two types of mutations cause some hyperbilirubinemia that could be compatible with the diagnosis of Gilbert syndrome. The incidence of the tighter abnormality is that gene incidence is 30%, and 9% of the general population of whites, blacks, and many Asians are homozygotes for Gilbert syndrome. In Japan, the incidence is less than 2%. However, some other mutations that are much less common in these other populations are found in Japan. Whether or not we call them Gilbert syndrome is a matter of semantics because the bilirubin levels in the homozygous form are 7 or 8, which would be compatible with Gilbert syndrome type II. In some of these cases, it has been claimed that in heterozygote form, it can also produce some bilirubin disorder. This is interesting because in CriglerNajjar syndrome, where there is total absence of enzyme activity, the heterozygotes don't have hyperbilirubinemia unless they also have Gilbert syndrome. Thus one would predict that there is a dominant negative conundrum. We have recently shown that the bilirubin EGT forms homodimers; two molecules bind to each other. Thus, it is possible that when an abnormal molecule forms a homodimer with a normal molecule, it reduces that activity. However, this reduction is very subtle and reduces the affinity either for UDPGA or for bilirubin in a very subtle manner. It is not clear that if you do an enzyme assay or a liver biopsy specimen using the usual assay method, an excess of UDPGA, if it is completely normal in these cases, but it's a matter of kinetics.
Dr. Gartner, can you define more specifically which Asian group you are referring to with regard to your breast-feeding data?
DR. GARTNER: We collected data for the first 7 days of life in all the Asian populations including Indian, Chinese, Japanese, Korean, and Philippine. These groups were compared with the British population living in Asia. All of the Asian native populations had elevated levels of jaundice in the newborn period compared with the British population. They varied within groups: the Japanese had the highest levels, followed by the Chinese and then the Indian populations. The data are also somewhat complicated by differences in breast-feeding rates and variations in breast-feeding methodology. The issue is complicated, but it appears that hyperbilirubinemia in the newborn period does appear to be more prevalent in Asians than in whites and blacks. In one study in Boston, the African American population had slightly lower levels of bilirubin compared with the white population. The difference didn't appear to reflect any genetic differences.
DR. YEUNG: In 1971, we reported the same result as that reported by Dr. Gartner for Hong Kong Chinese. In a recent study in southern China, Guangzhou, and Northwest Provinces, a similar sort of trend was found, but it was no longer true for the Hong Kong population. In the more recent survey on the infants from birth to the end of the first week, the peak bilirubin is not as high as in our study; the severity had declined. I don't think the problem is genetically related. It's not an ''Oriental problem.'' There might be a genetic predisposition, but there must be a very strong environmental input to make such a difference in the incidence of jaundice in 1971 versus today.
DR. STEVENSON:
We have looked at the production rates in a number of the populations in Asia and have found differences among subgroups over time. Production rates were higher in the past than they are now. This also suggests that environmental factors have an impact, so it's the interaction of genetics and environment that produce different transitional patterns after birth.
DR. CHOWDHURY:
Is this seen only in newborns, or also later? DR. GARTNER: Just newborns. DR. STEVENSON: I have not studied older patients, although it could be done if certain adaptations were made. We saw also differences in the American Indian populations, not all of whom migrated with the same waves, and so their genetic makeup is slightly different. The Hispanic population is the most unpredictable because it's a mix of Indian from Asia and also European. This makes it hard to predict events in an individual infant.
DR. FANAROFF: We have heard a lot this morning about the importance of elimination. In the fetus, bilirubin enters the amniotic fluid through the lungs. Is there any evidence that, after delivery and under circumstances of high loads, there is any pulmonary excretion of bilirubin?
DR. STEVENSON: I can't answer your question definitively, but many of you are probably aware of what was described a long time ago in the literature as yellow hilum membranes. There is no question that there is bilirubin in the lung. My colleague, Dr. Dennery, has hypothesized that perhaps it serves a protective function. We also know, however, that it disrupts surfactant films, so its actual role is not clear.
DR. DENNERY: To clarify, I don't think I said it is protective but rather than there could be two facets to its function. In pathologic conditions, excessive bilirubin is likely not protective. Many studies, even in adult populations, show that in cases of asthma or cystic fibrosis with high levels of inflammation, there is decreased production of carbon monoxide. Some of the proponents of the protective role of bilirubin or heme oxygenase and bilirubin and its by-product have suggested that this is a compensatory protective response, but it's difficult to believe that there would be more signs of carbon monoxide excretion in these inflammatory conditions and that treatment with anti-inflammatory agents such as dexamethasone would reduce carbon monoxide production. That seems to go along with the fact that in those circumstances, this is an abnormal and pathologic event rather than a beneficial event.
DR. GARTNER: In the course of doing our monkey experiments, both newborn and adult, we infused large amounts of unconjugated bilirubin. At the end of the experiments, after sacrificing the animals, we measured bilirubin concentrations in all the tissue. The highest unconjugated concentration per gram of tissue was in lung, specifically in the alveolar lining. It was higher than in any other organ except the liver itself. In other experiments, we showed that phospholipids, particularly lecithin, was a good solvent for unconjugated bilirubin. So bilirubin does appear to partition into the areas where the high phospholipid concentration is.
DR. BHUTANI: Dr. Stevenson, you adjusted the measurement of ETCO to body weight. Is there any data that adjusts to alveolar ventilation? Have any studies evaluated the role of alveolar hyperoxemia in infants with high bilirubin levels as well as the alveolar production of ETCO? DR. STEVENSON: With respect to carboxy hemoglobin levels in the presence of sustained hyperventilation, there is a direct, albeit altered, relationship between bilirubin levels and alveolar ventilation. The carboxy hemoglobin level is no longer a valid index of production rates relative to other individuals because there is a new equilibrium.
Your other question -whether there is some other way to index it, particularly if there are other sources of carbon monoxide, under some of the conditions that we create which are iatrogenic as we expose kids to high oxygen and they are immature and deficient in antioxidant defense -I don't know how this could be achieved, but it's an important question because it may be that under these abnormal conditions, part of the excretion rate of carbon monoxide reflects that those are local events that are not enzymatic and, in fact, may have implications for local biology. There is no question that carbon monoxide can come from lipid peroxidation or photooxidation, so we may have to do some other kind of indexing to understand what that means in these individuals. The indexing to body weight, which is adequate for use as an index for heme catabolism, may not be appropriate in these very abnormal circumstances where there is lung pathology.
DR. CASHORE: In our piglet studies, although we did not measure lung bilirubin, we made observations similar to those made by Dr. Gartner. The lung was very yellow at the end of the experiment. But I have another speculation related to the growing number of anecdotal cases of kernicterus in North America; that is, we are not very good at identifying G6PD deficiency in most of the North American population. In Nigeria, Israel, and Hong Kong, environmental factors seem to be at work. Perhaps we need to look more carefully at what those environmental factors might be in the North American population. One not quite environmental factor could certainly be gestational age (i.e., slightly less than term), but I also wonder about such things as dietary supplements, multi-ingredient, overthe-counter medications, and herbal medications, all of which might be used more often by younger people in North America today than in previous generations. Could these substances interact somehow with both the genetic variability and breastfeeding practices?
DR. KAPLAN: The problem with the G6PD deficiency is that it is very unusual to find an identifiable substance that causes the acute hemolysis. There are so many detergents and chemical agents and spices and all sorts of chemical substances on the market today for use in both the home and hospital. Nevertheless, your point is important to consider. Many groups in the United States have G6PD deficiency. African Americans have an incidence of between 11% and 13%. It would be relatively easy to screen these infants at birth, at least to determine who has G6PD deficiency at discharge 48 hours later. It will be difficult screening the females, but some of them could be screened and all of the males could be screened. This would identify an at-risk population. There are many Asians and
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